Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XVenD in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT05530421Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Mar 2023
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor and venetoclax in multiple myeloma (MM), sponsored by University of Miami. Primary endpoint: Overall Response Rate at 3 years. Started Mar 2023; status: recruiting.
02
Drugs
selinexorvenetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05530421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05530421.